Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease
about
Lipid-lowering efficacy of atorvastatinLipid lowering efficacy of atorvastatinMechanisms of fibrin polymerization and clinical implicationsStatin use following intracerebral hemorrhage: a decision analysis.Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnosticsIncreased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary EmbolismCorrelation of Inflammation and Lipoprotein (a) with Hypercoagulability in Hemodialysis Patients.Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease.Statin use after intracerebral hemorrhage: a 10-year nationwide cohort study.The association of statin therapy with the risk of recurrent venous thrombosis.Fibrin(ogen) and thrombotic disease.Why does aspirin decrease the risk of venous thromboembolism? On old and novel antithrombotic effects of acetyl salicylic acid.The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen).Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis.Structural properties of fracture haematoma: current status and future clinical implications.Reduced plasma fibrin clot permeability and susceptibility to lysis are associated with increased risk of postthrombotic syndrome.Characterisation of clot microstructure properties in stable coronary artery disease.Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.Weight reduction is associated with increased plasma fibrin clot lysis.Impaired fibrinolysis is associated with the severity of aortic stenosis in humans.
P2860
Q24187301-F6F6DEA2-5886-4EFE-BB43-9E42EBD7B54DQ24202363-AEDA79D7-5789-4628-85DF-945F16F223C8Q26865281-31B7A702-2AD1-46AC-88DE-E49F4C40B80AQ35170660-371AC21C-C6FB-420C-8613-CC8E09D8278AQ35189544-F456EF0E-8537-4360-8332-742FBBDC288EQ35535747-4B6A1FF3-18CC-4A2C-B943-EF63C5D160BAQ35920702-32C3B75F-4A42-4B36-8D80-7CE4A2E840AAQ36176347-9CEA2CD7-A039-496B-A31A-316DCBE31D55Q36546041-0E9CB731-70D5-40E4-A9AB-132637ADC755Q36903009-8CB8D08F-6D58-45E8-AF82-387984CE1776Q37138335-63E3B63C-18DD-4AF2-A942-48F0191369D6Q38117741-BA78E51C-9BC0-44FE-ABEC-E9A47661FC03Q38248477-CA0B4632-A365-4934-9687-D5FADE844B5BQ38261764-E3DF3CDA-7B76-488C-BE7F-2A931BC691D3Q38603046-FC036CCD-54A9-41A3-9579-2EAB70A1D2AAQ38663001-D26891FD-6062-4DD6-A91F-8D028EEE75DFQ38843077-4A9D2CDE-F858-4A36-9A88-298CBD21FD85Q40087127-435E41CD-CF92-46B8-8B56-0EBB1B5E57F0Q41045595-8AD5F95F-EFF2-4F59-ADB7-1A1F571F4012Q42245018-CC0DBA45-7ED5-4DEF-A44A-803DCE35B945Q42332549-2DCA3209-204E-4DD5-85FE-745AE44CA87FQ46769026-A6207AEC-8A1B-4BE8-8771-A01146C2B41CQ51283131-854C3489-FEB8-4CDE-B69D-B7C971F2ADDC
P2860
Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Statins, fenofibrate, and quin ...... s with coronary artery disease
@ast
Statins, fenofibrate, and quin ...... s with coronary artery disease
@en
Statins, fenofibrate, and quin ...... s with coronary artery disease
@nl
type
label
Statins, fenofibrate, and quin ...... s with coronary artery disease
@ast
Statins, fenofibrate, and quin ...... s with coronary artery disease
@en
Statins, fenofibrate, and quin ...... s with coronary artery disease
@nl
prefLabel
Statins, fenofibrate, and quin ...... s with coronary artery disease
@ast
Statins, fenofibrate, and quin ...... s with coronary artery disease
@en
Statins, fenofibrate, and quin ...... s with coronary artery disease
@nl
P2093
P2860
P3181
P1476
Statins, fenofibrate, and quin ...... s with coronary artery disease
@en
P2093
M Celinska-Löwenhoff
T Löwenhoff
P2860
P304
P3181
P356
10.1111/J.1538-7836.2006.01882.X
P407
P577
2006-05-01T00:00:00Z